

Title (en)  
VISFATIN THERAPEUTIC AGENTS FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS

Title (de)  
THERAPEUTISCHE VISFATINMITTEL ZUR BEHANDLUNG VON AKNE UND ANDEREN LEIDEN

Title (fr)  
AGENTS THÉRAPEUTIQUES DE VISFATINE POUR TRAITER L'ACNÉ ET D'AUTRES CONDITIONS

Publication  
**EP 2400980 A4 20130327 (EN)**

Application  
**EP 10745884 A 20100106**

Priority  
• IL 2010000011 W 20100106  
• US 20838609 P 20090224  
• US 26145309 P 20091116

Abstract (en)  
[origin: US2010215634A1] The present disclosure relates to compositions and methods for treating acne and other conditions. In particular, the compositions and methods are useful for the treatment of sebum associated conditions.

IPC 8 full level  
**A61K 38/45** (2006.01); **A61K 8/64** (2006.01); **A61K 8/92** (2006.01); **A61K 9/00** (2006.01); **A61K 9/06** (2006.01); **A61K 31/7052** (2006.01); **A61K 38/16** (2006.01); **A61P 17/00** (2006.01); **A61Q 19/00** (2006.01); **C12N 15/113** (2010.01)

CPC (source: EP KR US)  
**A61K 8/64** (2013.01 - EP US); **A61K 8/922** (2013.01 - EP US); **A61K 8/925** (2013.01 - EP US); **A61K 9/0014** (2013.01 - EP US); **A61K 9/06** (2013.01 - EP US); **A61K 31/18** (2013.01 - EP KR US); **A61K 31/4545** (2013.01 - EP US); **A61K 31/7052** (2013.01 - EP US); **A61K 31/7105** (2013.01 - KR); **A61K 38/16** (2013.01 - KR US); **A61K 38/45** (2013.01 - EP US); **A61P 1/02** (2017.12 - EP); **A61P 3/02** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 17/08** (2017.12 - EP); **A61P 17/10** (2017.12 - EP); **A61P 17/16** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **A61Q 19/008** (2013.01 - EP US); **C12N 15/113** (2013.01 - US); **C12N 15/1137** (2013.01 - EP US); **C12Y 204/02012** (2013.01 - EP US); **C12N 2310/11** (2013.01 - EP US); **C12N 2310/14** (2013.01 - EP US)

Citation (search report)  
• [X] WO 2006072809 A2 20060713 - ROBERTS RES INST [CA], et al  
• [E] WO 2010023307 A1 20100304 - TOPOTARGET AS [DK], et al  
• [X] WO 2008026018 A1 20080306 - APOXIS SA [CH], et al  
• [A] US 5110801 A 19920505 - LEVEEN HARRY H [US], et al  
• [A] US 4843096 A 19890627 - STIEFEL WERNER K [US]  
• See references of WO 2010097788A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

Designated extension state (EPC)  
AL BA RS

DOCDB simple family (publication)  
**US 2010215634 A1 20100826**; AU 2010217213 A1 20110804; AU 2010217213 B2 20130523; CA 2751156 A1 20100902; CN 102325789 A 20120118; CN 103800903 A 20140521; EP 2400980 A2 20120104; EP 2400980 A4 20130327; EP 2400980 B1 20160831; ES 2601827 T3 20170216; JP 2012518630 A 20120816; JP 2015051973 A 20150319; JP 2016183147 A 20161020; JP 6140120 B2 20170531; KR 101397912 B1 20140529; KR 20110131187 A 20111206; KR 20130095835 A 20130828; MX 2011007970 A 20111019; NZ 594067 A 20130328; NZ 600583 A 20130830; RU 2011138183 A 20130410; US 2015065432 A1 20150305; US 9393284 B2 20160719; WO 2010097788 A2 20100902; WO 2010097788 A3 20101021; WO 2010097788 A9 20110407; ZA 201105284 B 20120926

DOCDB simple family (application)  
**US 65279810 A 20100106**; AU 2010217213 A 20100106; CA 2751156 A 20100106; CN 201080008874 A 20100106; CN 201310291486 A 20100106; EP 10745884 A 20100106; ES 10745884 T 20100106; IL 2010000011 W 20100106; JP 2011550698 A 20100106; JP 2014196409 A 20140926; JP 2016051289 A 20160315; KR 20117019513 A 20100106; KR 20137018539 A 20100106; MX 2011007970 A 20100106; NZ 59406710 A 20100106; NZ 60058310 A 20100106; RU 2011138183 A 20100106; US 201414474142 A 20140831; ZA 201105284 A 20110718